title: Review of the safety and efficacy of ustekinumab.
abstract: Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.
authors.affiliation: Jill Roberts Associate Professor of Clinical Medicine and Director of Jill Roberts Center for Inflammatory Bowel Disease, Weill Medical College of Cornell University/New York Presbyterian Hospital, 425 East 61st Street, 10th Floor, New York, NY 10021, USA.
authors.forename: Ellen J
authors.initials: EJ
authors.lastname: Scherl
authors.forename: Sheila
authors.initials: S
authors.lastname: Kumar
authors.forename: Ryan U
authors.initials: RU
authors.lastname: Warren